A previous study including 39 patients covering the MASLD spectrum did not reveal any difference in global CD34 staining between patients with MASL and those without MASLD, which is in line with our observation when only global CD34 staining was compared.25 This evidence concerns the gene MAS1L and metabolic dysfunction-associated steatotic liver disease.